Evidence map›Paper›PMID 33400373›Full record

ArticleJournal of diabetes investigation2021

Association of protein tyrosine phosphatase 1B gene polymorphism with the effects of weight reduction therapy on bodyweight and glycolipid profiles in obese patients.

Hajime Yamakage, Yousuke Konishi, Kazuya Muranaka, Kikuko Hotta, Yoshihiro Miyamoto, Hiroko Morisaki, Takayuki Morisaki, Noriko Satoh-Asahara

Open access · goldAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Journal of diabetes investigation, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed
0.9field-weighted citation impact, top 28% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

4 citing papers in PubMed, 14 citations in OpenAlex.

  1. Article
  2. Review
  3. Review
  4. Antidiabetic Effect of StandardizedJournal of pharmacopuncture · 2023
    Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors at 5 institutions in 1 country.

Hajime YamakageDepartment of Endocrinology, Metabolism and Hypertension Research, Clinical Research Institute, National Hospital Organization Kyoto Medical Center, Kyoto, Japan.
Yousuke KonishiDepartment of Endocrinology, Metabolism and Hypertension Research, Clinical Research Institute, National Hospital Organization Kyoto Medical Center, Kyoto, Japan.
Kazuya MuranakaDepartment of Endocrinology, Metabolism and Hypertension Research, Clinical Research Institute, National Hospital Organization Kyoto Medical Center, Kyoto, Japan.
Kikuko HottaLaboratory of Pathophysiology and Pharmacotherapeutics, Faculty of Pharmacy, Osaka Ohtani University, Osaka, Japan.
Yoshihiro MiyamotoOpen Innovation Center, National Cerebral and Cardiovascular Center, Osaka, Japan.
Hiroko MorisakiDepartment of Medical Genetics, Sakakibara Heart Institute, Tokyo, Japan.
Takayuki MorisakiDivision of Molecular Pathology, The Institute of Medical Science, The University of Tokyo, Tokyo, Japan.
Noriko Satoh-AsaharaDepartment of Endocrinology, Metabolism and Hypertension Research, Clinical Research Institute, National Hospital Organization Kyoto Medical Center, Kyoto, Japan.ORCID https://orcid.org/0000-0002-8645-3144
Kyoto Medical Center · JPNational Cerebral and Cardiovascular Center · JPOsaka Ohtani University · JPSakakibara Hospital · JPThe University of Tokyo · JP

Funding

Japan Society for the Promotion of Science Exploratory Research/JP18K19769Japan Society for the Promotion of Science Research Activity start-up/19K21525Japan Society for the Promotion of Science Scientific Research (B)/JP18H02737Japan Society for the Promotion of Science Scientific Research (C)/JP19K07905National Hospital Organization Clinical research/H26-GENE-03Suzuken Memorial FoundationTANITA Healthy Weight Community Trust
6 · The paper itself

Abstract

AIMS/

introductionWeight reduction therapy is the primary treatment to prevent complications of obesity, such as lifestyle diseases and cardiovascular disease; however, to date, useful methods and genetic factors for predicting the outcomes of weight reduction therapy in obese patients have not been established. Protein tyrosine phosphatase 1B (PTP1B), a negative regulator for insulin and leptin signaling, potentially modulates glucose and energy homeostasis. This study aimed to investigate the contribution of PTPN1 polymorphisms on weight reduction and diabetes in obese Japanese patients. MATERIALS AND

methodsPTPN1-tagged single-nucleotide polymorphisms (SNPs) rs3787348 and rs6067484 were genotyped in 447 obese Japanese patients from the general population. In this prospective cohort study, all obese patients underwent a 3-month weight reduction therapy with lifestyle modifications, as recommended by guidelines.

resultsIn obese patients (male/female 196/251, age 50 ± 15 years, body mass index [BMI] 32 ± 6 kg/m

conclusionsOur findings show that the SNP rs3787348 in PTPN1 was associated with the effects of weight reduction therapy on BMI and waist circumference among obese Japanese patients.

Indexed as

AdultAgedAllelesBody Mass IndexBody WeightCohort StudiesEnergy MetabolismFemaleGlycolipidsHumansJapanLife StyleMaleMiddle AgedObesityPolymorphism, GeneticGlycolipidsProtein Tyrosine Phosphatase, Non-Receptor Type 1PTPN1 protein, humanObesityProtein tyrosine phosphatase 1BWeight reduction therapy

Identifiers

PMID33400373
PMCPMC8354504
OpenAlexW3118753843

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.